Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.

Article  PubMed  Google Scholar 

Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomark Prev. 2018;27:619–26.

Article  CAS  Google Scholar 

Yu K, Lee CH, Tan PH, Tan P. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res. 2004;10:5508–17.

Article  CAS  PubMed  Google Scholar 

Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106:dju055.

Article  PubMed  PubMed Central  Google Scholar 

Paquet ER, Hallett MT. Absolute assignment of breast cancer intrinsic molecular subtype. J Natl Cancer Inst. 2015;107:357.

Article  PubMed  Google Scholar 

Mullan PB, Millikan RC. Molecular subtyping of breast cancer: opportunities for new therapeutic approaches. Cell Mol Life Sci. 2007;64:3219–32.

Article  CAS  PubMed  Google Scholar 

Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382:597–609.

Article  CAS  PubMed  Google Scholar 

Swain SM, Miles D, Kim S-B, Im Y-H, Im S-A, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:519–30.

Article  CAS  PubMed  Google Scholar 

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–21.

Article  CAS  PubMed  Google Scholar 

Fan P, Xu K. Antibody-drug conjugates in breast cancer: marching from HER2-overexpression into HER2-low. Biochim Biophys Acta Rev Cancer. 2023;1878: 188849.

Article  CAS  PubMed  Google Scholar 

Yaghoobi V, Martinez-Morilla S, Liu Y, Charette L, Rimm DL, Harigopal M. Advances in quantitative immunohistochemistry and their contribution to breast cancer. Expert Rev Mol Diagn. 2020;20:509–22.

Article  CAS  PubMed  Google Scholar 

Rakha EA, Tan PH. Immunohistochemistry in Breast Cancer: Practice Points and Pitfalls. Pathobiol J Immunopathol Mol Cell Biol. 2022;89:261–2.

Article  Google Scholar 

Vuong D, Simpson PT, Green B, Cummings MC, Lakhani SR. Molecular classification of breast cancer. Virchows Arch Int J Pathol. 2014;465:1–14.

Article  CAS  Google Scholar 

Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, et al. NCCN task force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Cancer Netw JNCCN. 2009;7(Suppl 6):S1–21.

CAS  PubMed  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, et al. antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol. 2020;38:1887–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mutai R, Barkan T, Moore A, Sarfaty M, Shochat T, Yerushalmi R, et al. Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. Breast. 2021;60:62–9.

Article  PubMed  PubMed Central  Google Scholar 

Denkert C, Seither F, Schneeweiss A, Link T, Blohmer J-U, Just M, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22:1151–61.

Article  CAS  PubMed  Google Scholar 

Yang M, Sun J, Liu L, Kong X, Lin D, Zhou H, et al. Clinicopathological characteristics of HER2-low breast cancer: a retrospective study. Sci Rep. 2023;13:12382.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng L, Zhang Y, Wang Z, Wang H, Hao C, Li C, et al. Comparisons of clinical characteristics, prognosis, epidemiological factors, and genetic susceptibility between HER2-low and HER2-zero breast cancer among Chinese females. Cancer Med. 2023;12(14):14937–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021;7:1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y, Ozaki Y, et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer. 2022;29:234–41.

Article  PubMed  Google Scholar 

Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, et al. Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol. 2022;8:1177–83.

PubMed  PubMed Central  Google Scholar 

Guven DC, Kaya MB, Fedai B, Ozden M, Yildirim HC, Kosemehmetoglu K, et al. HER2-low breast cancer could be associated with an increased risk of brain metastasis. Int J Clin Oncol. 2022;27:332–9.

Article  CAS  PubMed  Google Scholar 

Li J-J, Yu Y, Ge J. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC. Breast Cancer. 2023;30:364–78.

Article  CAS  PubMed  Google Scholar 

Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria. Arch Pathol Lab Med. 2014;138:213–9.

Article  PubMed  Google Scholar 

Almstedt K, Heimes A-S, Kappenberg F, Battista MJ, Lehr H-A, Krajnak S, et al. Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. Eur J Cancer. 2022;173:10–9.

Article  CAS  PubMed  Google Scholar 

Li Y, Abudureheiyimu N, Mo H, Guan X, Lin S, Wang Z, et al. In real life, low-level HER2 Expression may be associated with better outcome in HER2-negative breast cancer: a study of the National Cancer Center. China Front Oncol. 2021;11: 774577.

Article  CAS  PubMed  Google Scholar 

Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.

Article  PubMed  Google Scholar 

McNamara MG, Lopes A, Wasan H, Malka D, Goldstein D, Shannon J, et al. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. J Hepatol. 2020;73:1109–17.

Article  CAS  PubMed  Google Scholar 

de Boniface J, Szulkin R, Johansson ALV. Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status: a Swedish National 6-year follow-up of 48 986 women. JAMA Surg. 2021;156:628–37.

Article  PubMed  PubMed Central  Google Scholar 

Xin L, Wu Q, Zhan C, Qin H, Xiang H, Xu L, et al. Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021). Chin Med J (Engl). 2022;135:697–706.

Article  CAS  PubMed  Google Scholar 

Won HS, Ahn J, Kim Y, Kim JS, Song J-Y, Kim H-K, et al. Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Res. 2022;24:22.

Article  CAS  PubMed  PubMed Central